Skip to main content
Ruthanna Davi on Muck Rack

Ruthanna Davi

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ruthanna

Contact Ruthanna, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia

|
By Max S. Topp, Bijal Shah, Elias Jabbour, Jae Park, Paul W. Shaughnessy, Aaron Logan, Karamjeet S. Sandhu, Mehrdad Abedi, Michael Bishop, Daniel DeAngelo, Xiang Yin, Ruthanna Davi, Katharine A. Hodby, Ram Malladi, Wolfram Brugger, Claire Roddie, Hagop Kantarjian, Justin Shang
| Nature Verified
Abstract In the single-arm Phase Ib/II FELIX study (NCT04404660), obecabtagene autoleucel (obe-cel; CD19-directed autologous CAR T-cell therapy) demonstrated high overall remission rates (ORR) and a favorable safety profile in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). To contextualize results from FELIX, we compared the efficacy and safety of obe-cel with matched external control arms (ECA) derived from historical trials using propensity score matching.
Open in Who Shared Issue with article?
See all 1 articles